OPEN CLINICAL EVALUATION OF SIDDHA MEDICINE NAGA SANGU PARPAM IN KABAYONI ROGAM ( VULVO VAGINAL CANDIDIASIS

PHASE 2 NON-RANDOMISED OPEN CLINICAL EVALUATION OF SIDDHA MEDICINE NAGA SANGU PARPAM IN KABAYONI ROGAM ( VULVO VAGINAL CANDIDIASIS)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2022/11/047334

Enrollment

Registered

2022-11-15

Start date

Unknown

Completion date

Unknown

Last updated

2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N908- Other specified noninflammatory disorders of vulva and perineum

Interventions

Intervention1: NAGA SANGU PARPAM: 130mg BD oral dose with butter after food for a period of 48 days Control Intervention1: Not applicable: Not applicable

Eligibility

Inclusion criteria

Inclusion criteria: Females of age between 18 to 45 yrs patients with whitish discharge Vulvovaginal itching erosions inflammation and erythematous surface is covered by whitish coat Positive candida albicans Diabetes mellitus

Exclusion criteria

Exclusion criteria: Sexually Transmitted diseases (Gonorrhoea,Syphilis,HIV) Non specific leucorrhoea Pregnancy and lactation Malignancy in uterus and Ovary Vulvovaginosis caused by other organism

Design outcomes

Primary

Measure	Time frame
Primary outcome is assessed by reduction in clinical symptoms like pruritis of vulva vulvovaginal inflammation and curdy white discharge.Timepoint: One week	—

Secondary

Measure	Time frame
Secondary outcome is mainly assessed by comparing the safety parameters before and after the treatmentTimepoint: 48 days	—

Countries

India

Contacts

Public ContactAMARAVATHY S

Government siddha medical College

nanbu.sumi@gmail.com9443279412

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026